Given the poor outcomes observed with radical prostatectomy (RP) and external-beam radiation therapy (EBRT), some in the urologic community contend that high-risk disease is not curable with currently available treatment strategies.[1,2] In fact, there is a growing contingent of clinicians who advocate the use of chemotherapy in conjunction with RP. With the established efficacy of brachytherapy, these efforts are likely excessive.
Long-term outcomes data now demonstrate excellent biochemical control rates among low- and intermediate-risk patients treated with interstitial brachytherapy.[3-6] Traditionally, there has been less enthusiasm for the use of brachytherapy in the setting of high-risk disease. This relates in large part to historical data suggesting suboptimal outcomes among high-risk patients treated with brachytherapy.[8-10] These studies are limited by their inadequate reporting of implant dosimetry and lack of planned treatment margins. Indeed, most modern trials show exceptional biochemical control rates among high-risk patients treated with a regimen that includes brachytherapy.[11-16]
Adverse pathologic features, which are characteristic of high-risk disease, correlate with a higher likelihood of extraprostatic extension and seminal vesicle involvement. This has led to the perception that patients with high-risk features may not be adequately treated with brachytherapy.[7,18,19] On the contrary, modern implant technique allows for generous extracapsular margins and treatment of the proximal seminal vesicles, with the added benefit of intraprostatic dose escalation. For these reasons, brachytherapy offers a unique advantage over other local therapies and is actually ideally suited for patients with the most aggressive local biology.
Several risk stratification systems have been developed. Nearly all are based on the premise that serum prostate-specific antigen (PSA), clinical T stage, and Gleason score are independent predictors of biochemical failure–free survival.[20-22] Perhaps most popular is the D'Amico system, which categorizes patients as low-risk (Gleason ≤ 6, PSA ≤ 10 ng/mL and stage T2a or less), intermediate-risk (Gleason 7, PSA 10–20 ng/mL, and/or stage T2b), or high-risk (Gleason 8–10, PSA > 20 ng/mL, and/or stage T2c or higher). In recent years, percent positive biopsies has also been identified as an independent predictor of biochemical outcome.[23-26]
Herein, we attempt to dispel some common misconceptions about prostate brachytherapy, and as a secondary objective, compare clinical outcomes with different treatment modalities. In doing so, we hope to convince the reader that brachytherapy is the best available local therapy and should be standard of care in the treatment of high-risk prostate cancer.
Risk of Extracapsular Extension
Early data published by D'Amico and others suggested better biochemical control rates among intermediate- and high-risk prostate cancer patients treated with RP or EBRT, as compared to those undergoing interstitial implant.[8-10] D'Amico's study, completed nearly a decade ago, continues to be cited as an argument against the use of brachytherapy in the setting of intermediate- and high-risk disease.
1. Nakabayashi M, Oh W: Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Curr Treat Options Oncol 5:349-355, 2004.
2. Oh W: Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol 21:229-234, 2003.
3. Sylvester J, Grimm P, Blasko J, et al: 15-Year biochemical relapse free survival in clinical T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 67:57-64, 2007.
4. Stock N, Stock R, Unger P: Intermediate term biochemical-free progression and local control following 125-I brachytherapy for prostate cancer. J Urol 173:803-807, 2005.
5. Wallner K, Merrick G, True L, et al: 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial. Radiother Oncol 75:307-310, 2005.
6. Zelefsky M, Yamada Y, Hunt M, et al: Comparison of 7-year outcomes between LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 69:S178, 2007.
7. National Comprehensive Cancer Network. Available at http://www.nccn.org. Accessed January 5, 2008.
8. D'Amico A, Whittington R, Malkowicz S, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 280:969-974, 1998.
9. Brachman D, Thomas T, Hilbe J, et al: Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate cancer in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48:111-117, 2000.
10. Kwok Y, DiBiase S, Amin P, et al: Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 53:588-594, 2002.
11. Stock R, Ho A, Cesaretti J, et al: Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66:389-394, 2006.
12. Stock R, Cahlon O, Cesaretti J, et al: Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59:1352-1359, 2004.
13. Sherertz T, Wallner K, Merrick G, et al: The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd 103 plus beam radiation therapy. Cancer J 10:301-306, 2004.
14. Merrick G, Butler W, Wallner K, et al: Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 68:34-40, 2007.
15. Dattoli M, Wallner K, True L, et al: Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110:551-555, 2007.
16. Merrick G, Butler W, Lief J, et al: Biochemical outcomes for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 8:322-327, 2002.
17. Partin A, Mangold L, Lamm D, et al: Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58:843-848, 2001.
18. Hakenberg O, Wirth M, Hermann T, et al: Recommendations for the treatment of localized prostate cancer by permanent interstitial brachytherapy. Urol Int 70:15-20, 2003.
19. Crook J, Lukka H, Klotz L, et al: Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer. CMAJ 164:975-981, 2001.
20. Kupelian P, Katcher J, Levin H, et al: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37:1043-1052, 1997.
21. D'Amico A, Whittington R, Kaplan I, et al: Equivalent biochemical failure free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys 37:1053-1058, 1997.
22. Kattan M, Easthan J, Stapleton A, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Ca Inst 90:766-771, 1998.
23. D'Amico A, Whittington R, Malkowicz S, et al: Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164-1172, 2000.
24. D'Amico A, Schultz D, Silver B, et al: Clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 49:679-684, 2001.
25. Merrick GS, Butler W, Galbreath R, et al: Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 52:664-673, 2002.
26. Rossi P, Clark P, Papagikos M, et al: Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Urology 67:349-353, 2006.
27. Stock R, Stone N, Tabert A, et al: A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41:101-108, 1998.
28. Kollmeier M Stock R, Stone N: Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57:645-653, 2004.
29. Orio P, Wallner K, Merrick G, et al: Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys 67:342-346, 2007.
30. Choi S, Wallner K, Merrick G, et al: Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J 10:175-180, 2004.
31. Merrick G, Wallner K, Butler W: Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. J Urol 169:1643-1652, 2003.
32. Frank S, Grimm P, Sylvester J et al: Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practive patterns in the United States. Brachytherapy 6:2-8, 2007.
33. Davis B, Pisansky T, Wilson T et al: The radial distance of extraprostatic extension of prostate carcinoma: Implications of prostate brachytherapy. Cancer 85:2630-2637, 1999.
34. Davis B, Haddock M, Wilson T et al: Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary? Tech Urol 6:70-77, 2000.
35. Sohayda C, Kupelian P, Levin H et al: Extent of extracapsular extension in localized prostate cancer. Urology 55:382-386, 2000.
36. Teh B, Bastasch M, Wheeler T, et al: IMRT for prostate cancer: Defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 56:184-191, 2003.
37. Chao K, Goldstein N, Yan D, et al: Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account to account for microscopic extension? Int J Radiat Oncol Biol Phys 65:999-1007, 2006.
38. Merrick G, Butler W, Wallner K, et al: Extracapsular radiation dose distribution after permanent prostate brachytherapy. Am J Clin Oncol 26:178-189, 2003.
39. Butzbach D, Waterman F, Dicker A: Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on post implant dosimetry. Int J Radiat Oncol Biol Phys 51:1196-1199, 2001.
40. Han B, Wallner K, Aggarwal S, et al: Treatment margins for prostate brachytherapy. Semin Urol Oncol 18:137-141, 2000.
41. Schwartz D, Sengupta S, Hillman D, et al: Prediction of radial distance of extraprostatic extension from pretherapy factors. Int J Radiat Oncol Biol Phys 69:411-418, 2007.
42. Nedea E, Wallner K, Reed D, et al: Extra-prostatic seed placement and its effect on seed loss. Cancer Journal (Scientific American) 11:147-151, 2005.
43. Merrick G, Butler W, Dorsey A, et al: Seed fixity in the prostate/periprostatic region following brachytherapy. In J Radiat Oncol Biol Phys 46:215-220, 2000.
44. Yossepowitch O, Eggener S, Bianco F, et al: Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 178:493-499, 2007.
45. Roach M, Marquez C, You H, et al: Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28:33-37, 1994.
46. Asbell S, Krall J, Pilepich M, et al: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: Analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 15:1307-1316, 1988.
47. Lawton C, DeSilvio M, Roach M, et al: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69:646-655, 2007.
48. Pommier P, Chabaud S, Lagrange J, et al: Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25:5366-5373, 2007.
49. Pollack A, Zagars G, Smith L, et al: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18:3904-3911, 2000.
50. Kuban D, Tucker S, Dong L, et al: Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67-74, 2008.
51. Jacob R, Hanlon A, Horwitz E, et al: Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 61:695-701, 2005.
52. Jacob R, Hanlon A, Horwitz E, et al: The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100:538-543, 2004.
53. Zelefsky M, Fuks, Hunt M, et al: High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876-881, 2001.
54. Swanson G, Hussey M, Tangen C, et al: Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25:2225-2229, 2007.
55. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005.
56. van den Ouden D, Hop W, Schroder F, et al: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160:1392-1397, 1998.
57. Lerner S, Blute M, Zincke H, et al: Extended experience with radical prostatectomy for clinical state T3 prostate cancer: Outcome and contemporary morbidity. J Urol 154:1447-1452, 1995.
58. Merrick G, Galbreath R, Butler W, et al: Patterns of death following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 69:S177, 2007.
59. Wallner K, Merrick G, Blasko J, et al: Prostate Brachytherapy Made Complicated, 3rd ed, pp 7.11-7.13. Seattle, SmartMedicine Press, 2008.
60. Stock R, Lo Y, Gaildon M, et al: Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined Pd-103 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 45:385-389, 1999.
61. Kestin L, Goldstein N, Vicini F, et al: Treatment of prostate cancer with radiotherapy: Should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 54:686-697, 2002.
62. Villers A, McNeal J, Redwine E, et al: Pathogenesis and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol 143:1183-1187, 1990.
63. Korman H, Watson R, Civantos F, et al: Radical prostatectomy: Is complete resection of the seminal vesicles really necessary? J Urol 156:1081-1083, 1996.
64. Ho A, Burri R, Jennings G, et al: Is seminal vesical implantation with permanent sources possible? A dose-volume histogram analysis in patients using combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy 6:38-43, 2007.
65. Swanson G, Riggs M, Hermans M: Pathologic findings at radical prostatectomy: Risk factors for failure and death. Urol Oncol 25:110-114, 2007.
66. Han M, Partin A, Pound C, et al: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28:555-565, 2001.
67. Babaian R, Troncoso P, Bhadkamkar V, et al: Analysis of clinico-pathologic factors predicting outcome after radical prostatectomy. Cancer 91:1414-1422, 2001.
68. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised controlled trial. Lancet 360:103-106, 2002.
69. Pilepich M, Winters K, Lawton C, et al: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61:1285-1290, 2005.
70. Hanks G, Pajak T, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 92-02. J Clin Oncol 21:3972-3978, 2003.
71. Critz F, Levinson K: 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 172:2232-2238, 2004.
72. Potters L, Morgenstern C, Calugaru E, et al: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173:1562-1566, 2005.
73. Roeske J, Forman J, Mesina C, et al: Evaluation of changes in the size and location of the prostate, seminal vesicles, bladder, and rectum during a course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 33:1321-1329, 1995.
74. Kupelian P, Langen K, Zeidan O, et al: Daily variations in delivered doses in patients treated with radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 66:876-882, 2006.
75. Kupelian P, Langen K, Willoughby T, et al: Image-guided radiotherapy for localized prostate cancer: Treating a moving target. Semin Radiat Oncol 18:58-66, 2008.
76. Bastian P, Gonzalgo M, Aronson W, et al: Clinical and pathologic outcome after prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 107:1265-1272, 2006.
77. Boorjian S, Karnes R, Rangel L, et al: Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 101:299-304, 2008.
78. Yossepowitch O, Eggener S, Bianco F, et al: Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 178:493-499, 2007.
79. Roehl K, Han Misop, Ramos C, et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172:910-914, 2004.
80. Mitsuyama H, Wallner K, Merrick G, et al: The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy. Am J Clin Oncol 30:597-600, 2007.
81. Potters L, Purrazzella R, Brustein S, et al: The prognostic significance of Gleason grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56:749-754, 2003.
82. Han M, Partin A, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003.
83. Brandli D, Koch M, Foster R, et al: Biochemical disease-free survival in patients with high prostate-specific antigen level (20-100 ng/ml) and clinically localized prostate cancer after radical prostatectomy. BJU Int 92:19-22, 2003.
84. Eastham J, Kelly W, Grossfeld G, et al: Cancer and Leukemia Group B (CALGB) 90203: A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62:55-62, 2003.
85. Glode L: The case for adjuvant therapy for prostate cancer. J Urol 176:S30-S33, 2006.
86. Prayer-Galetti T, Sacco E, Pagano F, et al: Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 100:274-280, 2007.
87. Clark P, Peereboom D, Dreicer R, et al: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57:281-285, 2001.
88. Krauss D, Martinez A, Ghilezan M, et al: A three-arm prospective randomized trial evaluating the role of androgen deprivation therapy in patients with high-risk prostate cancer treated with combination external beam radiotherapy and brachytherapy boost. William Beaumont Hospital, Department of Radiation Oncology (unpublished data).